Published in final edited form as:

Bioorg Med Chem Lett. 2007 January 15; 17(2): 533–537.

Development of SPECT imaging agents for the norepinephrine transporters: [¹²³I]INER[†]

Gilles D. Tamagnan^{a,b,*}, Eric Brenner^b, David Alagille^a, Julie K. Staley^b, Colin Haile^b, Andrei Koren^a, Michelle Early^a, Ronald M. Baldwin^b, Frank I. Tarazi^c, Ross J. Baldessarini^c, Nachwa Jarkas^d, Mark M. Goodman^d, and John P. Seibyl^{a,b}

^a Institute for Degenerative Diseases, New Haven CT 06520

^b Yale University School of Medicine, VA Connecticut HCS (116A2), 950 Campbell Avenue, CT 06516, USA

^c Department of Psychiatry and Neuroscience Program, Harvard Medical School and Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA 02478-9106 USA.

^d Emory University, Atlanta GA.

Abstract

A series of reboxetine analogs was synthesized and evaluated for in vitro binding as racemic mixtures. The best candidate (INER) was synthesized as the optically pure (S,S) enantiomer, labeled with iodine-123 and its in vivo binding determined by SPECT imaging in baboons. The in vivo specificity, selectivity and kinetics of [¹²³I]INER make it a promising agent for imaging NET in vivo by noninvasive SPECT imaging.

The norepinephrine transporter (NET) is a protein with twelve transmembrane-spanning domains, located at the pre-synaptic terminal of noradrenergic neurons. The principal physiological function of NET is to remove excess norepinephrine (NE) from the synaptic cleft to terminate the action of NE (avoiding over-stimulation) and to recycle NE into the pre-synaptic neuron (active reuptake) for later re-release. Brain structures known to be rich in NET include the locus coeruleus, (brainstem area); thalamus, hippocampus and throughout the cerebral cortex, whereas low densities are found in cerebellum and striatum.⁴ NET has been implicated in the pathophysiology of numerous neuropsychiatric and neurodegenerative disorders, including depression (reduced level of NE in the synapse appears to down-regulate the level of NET),^{5,6} arousal,⁷ anxiety,^{8,9} attention-deficit/hyperactivity disorder (atomoxetine **1** is the first non-stimulant selective NET inhibitor for the treatment of ADHD^{10,11} and Alzheimer's disease.¹² Therefore, the development of a specific radioligand to quantify the variation of NET density in vivo will be of great utility as a diagnostic tool to better understand the etiology and pathogenesis of these neuropsychiatric disorders, as well as a tool to evaluate potential new drugs targeting the NET.

[†]Preliminary results of these experiments have been reported at scientific conferences for imaging 1. Tamagnan, G. D.; Haile, C. N.; Brenner, E.; Koren, A. O.; Bois, F.; Amici, L.; Baldwin, R. M.; Seibyl, J. P.; Staley, J. K. *EJNM* **2005**, 32, 287, 2. Brenner, E.; Baldwin, R. M.; Tamagnan, G. D. *Organic Letters* **2005**, 7, 937-939, 3. Brenner, E.; Baldwin, R. M.; Tarazi, F.; Baldessarini, R. J.; Tamagnan, G. D. *The 229th ACS National Meeting, in San Diego, CA, March 13-17, 2005* **2005**.

*Corresponding author. E-mail: gtamagnan@inidd.org

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Research on quantitative mapping of dopamine transporter (DAT) and serotonin transporter (SERT) related to various CNS disorders has benefited from the availability of suitable radioligands (e.g., β -CIT as DAT radioligand,^{13,14} and DASB or ZIENT as SERT radioligands^{15,16}). In contrast, brain imaging of NET has been hampered by lack of a suitable radioligand. However in the past few years some selective NET radioligands have been prepared and evaluated in animals. [¹¹C]Nisoxetine¹⁷ **2** showed significant binding in NET-rich tissue in mouse brain but also a high nonspecific binding and unfavorable slow kinetics, which excludes it as a practical NET imaging agent. Recently, several research groups have reported the evaluation of derivatives of reboxetine (**3**) with more promising properties than the nisoxetine series. [¹¹C]MeNER¹⁸⁻²⁰ **4** has shown the highest hypothalamus/striatum ratio of 2.5 at 60 min in rats, corresponding to the relative distribution of NET and SERT²¹. Displacement study using reboxetine or desipramine as selective NET inhibitor pretreatment reduced this ratio to unity, whereas selective DAT and SERT inhibitors did not significantly affect the ratio.¹⁸ However, the long time to achieve peak uptake (> 90min) makes this radioligand unsuitable for PET imaging¹⁹. From a statistical point of view it is not optimal to obtain the maximal specific binding at the end of the experiment when the signal to noise ratios are decreasing due to rapid decay of the carbon-11 (half-life = 20 min), although these issues are not as critical for SPECT imaging owing to the longer half life of typical SPECT radionuclides (¹²³I, 13.2 h, ¹¹¹In, 2.8 days). In the nisoxetine series, (R)-[¹²⁵I]MIPP **5** showed good in vitro affinity for NET and moderate affinity for SERT, which, when combined with the significantly higher density of SERT compared to NET, decreased the selectivity for NET in vivo.

We recently reported a new asymmetric synthesis² which we used to synthesize new analogs of reboxetine. We report here the synthesis, in-vitro evaluation of new reboxetine analogs as potential NET imaging agent as well as the in vivo evaluation of the most promising agent in this series.

Since in the reboxetine series, the most active isomer always corresponds to the S,S isomer, in order to rapidly discriminate the future candidate we decided to first synthesize the racemic compounds (mixture S,S/R,R) and then to pursue the most promising candidates with the evaluation of the S,S enantiomer. The synthesis of the new compounds is summarized in scheme 1. The key intermediate **11** was synthesized in good yield starting from the racemic aminopropanediol **6** in five steps (detail of the synthesis was described previously²). Subsequent condensation of substituted diaryl or diheteroaryl zinc provide a mixture of racemic diastereomers **12** and **13** easily separated by chromatography. The racemic (S,S/R,R) reboxetine analogs N-Boc protected **14a-i** were obtained from **12** and **13**, using either a Mitsunobu reaction (starting from **12**) or by a direct nucleophilic substitution of the appropriate 2-fluoro benzene tricarbonylchromium complex (starting from **13**). Deprotection of compounds **14a-i** was achieved in quantitative yield using trifluoroacetic acid. Compounds **15a-i** were evaluated in vitro against all three monoamine transporters, using cell membrane-containing homogenates of rat forebrain (frontoparietal cerebral cortex for SERT and NET, caudate-putamen for DAT) as transporter sources (Table 1).

All compounds showed a better activity at NET than at the other monoamine transporters (DAT and SERT) except for compound **15f**, which was slightly more active at the DAT. In this series, compound **15a** is of particular interest, with a binding affinity of 2.5 nM for the racemic mixture. The introduction of an iodine at position 3 of the phenyl moiety (compound **15b-15e**) led to a decrease of the affinity. Replacement of the phenoxy by a benzyloxy moiety (**15f-g**) led to less active compounds (15.4 nM vs 73.8 nM for **15b** vs **15g**). Replacement of the phenyl ring by a thiophene reduced the activity of the compounds compared to the parent.

These results indicate that compound **15a** shows the most promise and thus we focused our effort on this structure. The enantiomeric pure synthesis was achieved using the same sequence illustrated in Scheme 1 but this time starting from the chiral (S)-(-)-3-amino-1,2-propanediol which led to INER (formal (2S,3S)-**15a**) with ee = 99% . INER was evaluated against all three monoamine transporters and show binding value $K_i = 0.84$ nM for NET and selectivity versus DAT and SERT (270 and 51 respectively, Table 2).

Radiolabeled [123 I]INER was prepared via iododestannylation of the tin precursor **16**, easily synthesized by palladium-catalyzed stannylation of Boc-INER (formal (2S,3S)-**14a**). Removal of the Boc protecting group with trifluoroacetic acid and HPLC purification led to [123 I]INER as described in Scheme 2. The lipophilicity of [123 I]INER was assessed by octanol-phosphate buffer (pH = 7.4) partition. The partition coefficient log D of [123 I]INER was 2.6, which is high in the range of values considered acceptable for good blood-brain barrier penetration²².

A series of SPECT imaging studies were conducted including both bolus-only and bolus plus continuous infusion of [123 I]INER in an ovariectomized female baboon (*Papio anubis*) to evaluate the regional brain uptake and washout of activity. Pharmacological specificity was assessed by blocking displacement experiments using reboxetine as selective NET antagonist and citalopram as SERT antagonist.

An initial study was performed by dynamic SPECT imaging after a single bolus injection of 7.89 mCi of [123 I]INER in an adult female olive baboon. The maximal radioactivity peak in the brain was obtained after 10 min, with 1% of the total injected dose, followed by a slow washout over more than 2 h. Regional brain tracer uptake is consistent with the distribution of NET in the baboon brain, with the highest uptake in locus coeruleus (brainstem) and thalamus (diencephalon), and lowest uptake in cerebellum and striatum. In the next study, [123 I]INER was administered as a loading bolus injection followed by constant infusion using a bolus to infusion ratio of 1.3 h (Figure 3), stable levels were obtained in less than 100 min. Regional distribution of radioactivity was identical to that obtained in the bolus experiment, which followed the established distribution of NET in the baboon brain.

To assess the pharmacological specificity, reboxetine was injected (1 mg/kg iv) at 210 min after administration of bolus-plus-constant infusion which resulted in a reduction of radioactivity in all brain regions. Reduction was more pronounced in the NET-rich regions, with up to 60% specific displacement. In contrast, displacement with citalopram (5 mg/kg) or methylphenidate (0.5 mg/kg) at 210 min pi did not show any displacement of [123 I]INER.

Recently, the same structure as compound **15a** was reported under the name 'IPBM' by Saji et al.²³ Results were comparable to those we have reported here.

In conclusion, we report the synthesis of nine racemic potential NET imaging agents. Of these, compound **15a** (INER) was the best candidate for further investigation and we developed an asymmetric synthesis leading to the enantiopure INER. INER showed high affinity for NET ($K_i = 0.84$ nM) and good selectivity versus DAT and SERT (270 and 51, respectively). We synthesized [123 I]INER and showed specific in vivo NET binding in baboon. Taken together, the in vivo specificity, selectivity and kinetics suggest that [123 I]INER is a promising agent for imaging NET in vivo using SPECT or PET.

REFERENCES

1. Tamagnan GD, Haile CN, Brenner E, Koren AO, Bois F, Amici L, Baldwin RM, Seibyl JP, Staley JK. EJNM 2005;32:287.
2. Brenner E, Baldwin RM, Tamagnan GD. Organic Letters 2005;7:937–939. [PubMed: 15727479]

3. Brenner E, Baldwin RM, Tarazi F, Baldessarini RJ, Tamagnan GD. The 229th ACS National Meeting, in San Diego, CA, March 13-17, 2005. 2005
4. Aston-Jone G, Foote S, Bloom F. Norepinephrine (Frontiers of Clinical Neuroscience, Vol 2) 1984:92–116.
5. Spillmann MK, Van der Does AJW, Rankin MA, Vuolo RD, Alpert JE, Nierenberg AA, Rosenbaum JF, Hayden D, Schoenfeld D, Fava M. Psychopharmacology 2001;155:123–127. [PubMed: 11400999]
6. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS. Archives of General Psychiatry 1996;53:117–128. [PubMed: 8629887]
7. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, van Dyck CH, Baldwin RM, Seibyl JP. Biological Psychiatry 2004;56:497–502. [PubMed: 15450785]
8. Hisamichi, Moon A,Y, Aoyagi A, Hara T, Abe K, Yamazaki R, Kumagae Y, Naruto S, Koyama K, Marumoto S, Tago K, Toda N, Takami K, Yamada N, Ori M, Kogen H, Kaneko T. Journal of Pharmacological Sciences 2003;93:95–105. [PubMed: 14501158]
9. Allgulander C, Hackett D, Salinas E. British Journal of Psychiatry 2001;179:15–22. [PubMed: 11435263]
10. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Neuropsychopharmacology 2002;27:699–711. [PubMed: 12431845]
11. Biederman J, Spencer T. Biol. Psychiatry 1999;46:1234–1242. [PubMed: 10560028]
12. Tejani-Butt SM, Yang J, Zaffar H. Brain Research 1993;631:147–150. [PubMed: 8298987]
13. Scanley BE, Al-Tikriti MS, Gandelman MS, Laruelle M, Zea-Ponce Y, Baldwin RM, Zoghbi SS, Hoffer PB, Charney DS, Wang S-Y, Neumeyer JL, Innis RB. European Journal of Nuclear Medicine 1995;22:4–11. [PubMed: 7698153]
14. Malison RT, McDougale CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, Price LH, Leckman JF, Innis RB. Am. J. Psychiat 1995;152:1359–1361. [PubMed: 7653693]
15. Chen P, Kilts CD, Galt JR, Ely TD, Camp VM, Malveaux EJ, Goodman MM. Journal of Nuclear Medicine 2000;41:39P.
16. Goodman MM, Chen P, Plisson C, Martarello L, Galt J, Votaw JR, Kilts CD, Malveaux G, Camp VM, Shi B, Ely TD, Howell L, McConathy J, Nemeroff CB. Journal of Medicinal Chemistry 2003;46:925–935. [PubMed: 12620070]
17. Haka MS, Kilbourn MR. Nuclear Medicine and Biology 1989;16:771–774. [PubMed: 2533589]
18. Wilson AA, Patrick Johnson D, Mozley D, Hussey D, Ginovart N, Nobrega J, Garcia A, Meyer J, Houle S. Nuclear Medicine and Biology 2003;30:85–92. [PubMed: 12623106]
19. Schou M, Halldin C, Sovago J, Pike VW, Gulyas B, Mozley PD, Johnson DP, Hall H, Innis RB, Farde L. Nuclear Medicine and Biology 2003;30:707–714. [PubMed: 14499328]
20. Schou M, Halldin C, Sóvágó J, Pike VW, Hall H, Gulyás B, Mozley PD, Dobson D, Shchukin E, Innis RB, Farde L. Synapse 2004;53:57–67. [PubMed: 15170818]
21. Smith HR, Beveridge TJR, Porrino LJ. Neuroscience 2006;138:703–714. [PubMed: 16427744]
22. Laruelle M, Slifstein M, Huang Y. Molecular Imaging & Biology 2003;5:363–375. [PubMed: 14667491]
23. Kanegawa, Kiyono Y, Kimura H, Sugita T, Kajiyama S, Kawashima H, Ueda M, Kuge Y, Saji H. EJNM 2006;33:639–647.

Figure 1.
Structure of NET ligand

Scheme 2a.

^a Reagents and conditions: a) $(\text{SnMe}_3)_2/\text{Pd}(\text{PPh}_3)_4/\text{DME}$; b) $\text{Na}[^{123}\text{I}]/\text{CH}_3\text{COOOH}/\text{H}_3\text{PO}_4$.

Figure 3.
Decay-corrected time activity curve in a baboon undergoing constant infusion of [^{123}I]INER.

Scheme 1.

^a Reagents and conditions: a) $\text{ClCH}_2\text{COCl}/\text{Et}_3\text{N}$; b) $\text{t-BuOK}/\text{t-AmOH}$; c) $\text{Red-Al}/\text{THF}$; d) $(\text{Boc})_2\text{O}/\text{NaOH}$; e) Trichloroisocyanuric acid/ $\text{TEMPO}/\text{NaHCO}_3$; f) $\text{Ar}_2\text{Zn}/\text{THF}$; g) $\text{R-OH}/\text{DIAD}/\text{PPh}_3/\text{THF}$; h) Fluorobenzenetricarbonylchromium complex/ NaH ; i) $\text{TFA}/\text{CH}_2\text{Cl}_2$.

Table 1

Affinity (K_i , nM) or SERT inhibition (% at 10 μ M) of reboxetine analogs.^a

Cpd	Structure ^b	NET	DAT	SERT	SERT Inhibition 40%	Cpd	Structure ^b	NET	DAT	SERT	SERT Inhibition
15a		2.47	410			15f		70.4	14.2	252	
15b		15.4	>10,000		12%	15g		73.8	71.6	351	
15c		27.6	740		24%	15h		71.9	186		31%
15d		28.5	3,139		44%	15i		79.6	210	141	
15e		101	1,871	486							

^a Assays of novel compounds employed cell membrane-containing homogenates of rat forebrain (frontoparietal cerebral cortex for SERT and NET, caudate-putamen for DAT), with [³H]paroxetine (0.17nM) for SERT (blank = 10mM R,S-fluoxetine, Sigma-RBI), [³H]GBR-12935 (0.20 nM) for DAT (blank = 10 mM GBR-12909, Sigma-RBI), and [³H]nisoxetine (0.40mM) for NET (blank = 10mM desipramine, Sigma-RBI); results are expressed as the mean of three separate determination.

^b All compounds are racemic mixtures; for clarity, just one enantiomer is represented.

Table 2

Binding affinity of INER (K_i, nM, mean ± SEM) ^a

Compound	NET	DAT	SERT	Selectivity NET vs DAT	Selectivity NET vs SERT
INER	0.84±0.12	228±6.9	40.4±10.4	270	51

^a Assays of INER employed cell membrane-containing homogenates of rat forebrain (frontoparietal cerebral cortex for SERT and NET, caudate-putamen for DAT), with [³H]paroxetine (0.17 nM) for SERT (blank = 10 mM R,S-fluoxetine, Sigma-RBI), [³H]GBR-12935 (0.20 μM) for DAT (blank = 10 μM GBR-12909, Sigma-RBI), and [³H]nisoxetine (0.40 nM) for NET (blank = 10 μM desipramine, Sigma-RBI); results are expressed as the mean of three separate determination.